Core Insights - Appili Therapeutics has submitted a total of seven U.S. government funding proposals, with a potential combined award value of up to US$137 million, aimed at advancing infectious disease and biodefense products [3][4][6] - The company has been accepted as a member of the U.S. Medical CBRN Defense Consortium, enhancing its partnerships in government and biodefense sectors [4][5] - Financial results for the first quarter of fiscal 2026 show a net loss of $1.2 million, a decrease from $1.6 million in the same period last year, attributed to reduced financing costs and lower research and development expenses [16] Funding Proposals - Appili has submitted seven non-dilutive funding proposals to U.S. government agencies, which include submissions to the Congressionally Directed Medical Research Program, the U.S. Medical CBRN Defense Consortium, and the National Institute of Allergy and Infectious Diseases [3][4] - If awarded, these funds will support the development of projects through manufacturing, non-clinical development, and regulatory activities necessary for IND submissions and Phase 1 clinical trials [3] Biodefense Initiatives - The company is advancing its live-attenuated vaccine candidate, ATI-1701, for the prevention of tularemia, with approximately US$11.6 million in funding from the U.S. Air Force Academy [6][7] - Recent data published indicates that ATI-1701 provides robust protection against lethal tularemia in non-human primates, supporting its potential as a leading vaccine candidate [7] Product Development - LIKMEZ, a metronidazole oral suspension, has been re-launched in the U.S. and is the first FDA-approved ready-to-use liquid formulation for patients who have difficulty swallowing tablets [10][11] - The company is also advancing ATI-1801, a topical formulation for cutaneous leishmaniasis, with positive Phase 3 data and ongoing efforts to secure non-dilutive funding for its development [12][14] Financial Overview - For the three months ended June 30, 2025, the company reported a net loss of $1.2 million, reflecting a decrease in financing costs and research and development expenses [16] - As of June 30, 2025, the company had cash reserves of $1.1 million, a slight decrease from $1.2 million at the end of the previous quarter [16]

Core Insights - Maui Land & Pineapple Company, Inc. reported strong financial performance with a 103% increase in operating revenues for the first half of 2025 compared to the same period in 2024, totaling $10,406,000 [3][9] - The company is focusing on maximizing land productivity and diversifying revenue streams, including launching an agave venture and improving leasing revenues, which increased by 46% year-over-year [2][3] Financial Performance - Operating revenues for the six months ended June 30, 2025, were $10,406,000, up from $5,128,000 in the same period in 2024, marking an increase of $5,278,000 [3][9] - Land development and sales revenues rose to $3,442,000 from $200,000, primarily due to contracting revenues from the Honokeana Homes Relief Housing Project [3][9] - Leasing revenues increased to $6,421,000 from $4,388,000, attributed to improved occupancy and updated leases [3][9] Costs and Expenses - Total operating costs and expenses for the first half of 2025 were $12,897,000, compared to $8,409,000 in 2024, an increase of $4,488,000 [3][9] - The increase in operating costs was mainly due to land development and sales costs of $3,157,000 related to the Honokeana Homes project [3][9] - Water and conservation costs rose to $1,253,000 from $709,000, reflecting increased operations and maintenance costs [3][9] Net Loss and Adjusted EBITDA - The net GAAP loss for the first half of 2025 was ($9,639,000), or ($0.49) per share, compared to a loss of ($3,247,000) or ($0.16) per share in 2024 [3][9] - Adjusted EBITDA for the six months ended June 30, 2025, was ($192,000), an improvement of $55,000 from ($247,000) in the same period in 2024 [3][9] Cash and Investments - Cash and Investments Convertible to Cash totaled $7,028,000 on June 30, 2025, down from $9,522,000 at the end of 2024, primarily due to pension termination contributions and development expenditures [3][9]

Core Viewpoint - The merger between Regional Health Properties, Inc. and SunLink Health Systems, Inc. is a transformative step aimed at creating a vertically integrated company that enhances growth, efficiency, and long-term value creation [2]. Company Overview - Regional Health Properties, Inc. is a self-managed healthcare real estate investment company focused on investing in real estate for senior living and long-term care [7]. Merger Details - The merger was completed on August 14, 2025, with Regional surviving as the merged entity [1]. - Each five shares of SunLink common stock were converted into 1.1330 shares of Regional common stock and one share of Regional Series D 8% Cumulative Convertible Redeemable Participating Preferred Shares [3]. - The total consideration for the merger included approximately 1,595,400 shares of Regional common stock and approximately 1,408,120 shares of Regional Series D preferred stock [3]. Leadership Structure - The combined company will be led by Brent S. Morrison as President and CEO, with Mark J. Stockslager as CFO and Robert M. Thornton, Jr. as Executive Vice President – Corporate Strategy [5]. - The Board of Directors will include members from both Regional and SunLink, ensuring continuity and integration of leadership [6]. Trading Information - The combined company will operate under the name Regional Health Properties, Inc. and will continue to trade under Regional's ticker symbols on the OTCQB [4].

MISSISSAUGA, Ontario, Aug. 14, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and six months ended June 30, 2025 on Thursday, August 21, 2025 after market hours. A presentation on the Company’s second quarter and first half 2025 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. About BioSyent Inc. Listed on the TSX Venture Exchange under ...

Financial Performance - Quarterly net revenues reached RMB 706.4 million (US$ 98.6 million), representing a year-over-year increase of 53.9% from RMB 458.9 million [6][9] - Quarterly net income was RMB 44.1 million (US$ 6.2 million), a significant improvement compared to a net loss of RMB 72.1 million in the same period last year [2][9] - For the first six months of 2025, total shipments surpassed those of the entire year of 2024, with net income reaching RMB 26.5 million (US$ 3.7 million) [2][9] Business Growth and Market Position - The second quarter saw a surge in growth momentum, with net revenues increasing over 50% year-over-year, driven by strong customer demand and operational execution [2] - The company secured numerous design wins for 20 models from 9 leading OEMs, including a platform win for multiple 2026 models with a top ADAS customer [2][3] - In the Robotics sector, the company ranked No. 1 in lidar shipments in China for the first half of 2025, indicating strong market leadership [2][7] Product and Technology Development - The company achieved the C-sample milestone for its long-range lidar sensor with a top European OEM, confirming product maturity and successful testing [3] - The long-range lidar debuted at the 2025 Shanghai Auto Show, showcasing its application in high-profile vehicles such as SAIC Audi's sports car and Cadillac VISTIQ SUV [3] - The company is positioned to capitalize on the growing demand for lidar technology in both automotive and robotics applications, leveraging its expertise and global scale [2][7] Operational Highlights - Total lidar shipments for the second quarter were 352,095 units, a remarkable increase of 306.9% from 86,526 units in the same period of 2024 [8] - ADAS lidar shipments reached 303,564 units, representing a 275.8% increase from 80,773 units in the corresponding period of 2024 [8] - The company reported a gross margin of 42.5% for the second quarter, slightly down from 45.1% in the same period last year, primarily due to a decrease in high-margin service revenues [9]

Millicom (Tigo) Reaches Strategic Agreement with EPM to facilitate Merger Process with ColTel Luxembourg, August 14, 2025 – Millicom (Tigo) today announced a key agreement with Empresas Públicas de Medellín (EPM) that advances its acquisition strategy in Colombia and unlocks a path toward the integration of Tigo-UNE and Colombia Telecomunicaciones (ColTel). Under the terms of the agreement: Millicom has committed to present an offer in EPM’s Law 226 sale process, subject to the terms published by EPM on Jul ...

Company Overview - Rein Therapeutics is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for orphan pulmonary and fibrosis indications [3] - The lead product candidate, LTI-03, is a synthetic peptide targeting alveolar epithelial cell survival and inhibiting profibrotic signaling, currently in clinical development [3] - The second product candidate, LTI-01, has completed Phase 1b and Phase 2a trials for loculated pleural effusions and has received Orphan Drug Designation in both the U.S. and E.U. [3] Upcoming Events - Chief Scientific Officer Cory Hogaboam will present at the IPF Summit 2025 on August 19-21, 2025, discussing the role of immune cells and inflammation in idiopathic pulmonary fibrosis (IPF) [2] - CEO Brian Windsor will present on August 21, focusing on innovative clinical trial design and lessons learned from the LTI-03 trial [2] Research and Development Focus - The presentations will cover the modulation of lung-resident macrophages and the potential of Caveolin-scaffolding domain (CSD) peptides in targeting multiple drivers of fibrosis [5] - Rein's Phase 2 trial of LTI-03 aims to enroll up to 120 patients, assessing safety, tolerability, and lung function as key outcomes [5] - The company is strategizing around patient recruitment and trial design to ensure relevance in a rapidly evolving treatment landscape [5]

Core Viewpoint - Flexible Solutions International, Inc. reported its financial results for the second quarter of 2025, highlighting an increase in sales and net income despite facing challenges such as tariff increases and soft sales [2][3]. Financial Performance - Sales for Q2 2025 were $11,367,132, representing an increase of approximately 8% compared to $10,528,739 in Q2 2024 [7]. - Net income for Q2 2025 was $2,028,912, or $0.16 per basic share, compared to $1,289,796, or $0.10 per basic share in Q2 2024 [7]. - The increase in earnings was largely attributed to research and development services sales, with some related expenses recognized in previous quarters [7]. Operational Developments - The NanoChem division and ENP subsidiary remain the primary sources of revenue and cash flow for the company [4]. - The company is transitioning its legacy production to Panama for international customers while expanding its food-grade business in Illinois [3][4]. - New opportunities are emerging in various sectors, including detergent, water treatment, oil field extraction, and food and nutrition supplement manufacturing [4]. Cash Flow Analysis - For the six months ended June 30, 2025, the company reported an operating cash flow of $4,253,875, or $0.34 per basic share, compared to $3,853,907, or $0.31 per basic share in the same period of 2024 [7][9]. - The basic weighted average shares used in computing earnings per share were 12,647,532 for Q2 2025, up from 12,450,532 in Q2 2024 [7].

NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Veea Inc. (NASDAQ: VEEA) (“Veea” or the “Company”), a leader in intelligent edge infrastructure, announced the closing of its public offering of an aggregate of 9,189,096 shares of common stock and warrants to purchase up to 9,189,096 shares of common stock at a combined offering price of $1.00 per share and accompanying warrant (the “Offering”). The Company received aggregate cash gross proceeds of approximately $6.0 million, before deducting placement agent fees ...

MELBOURNE, Australia, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced it has acquired Telecare, an innovative, Australian tech-enabled provider of specialist and allied health care via virtual delivery. Telecare operates Australia's leading virtual care clinic and provides software solutions to the healthcare sector. With over 300 virtual specialists in over 30 specialties, supporting both GP-referred appointments as well as providing virtual ...